Meet the Team
Ai2 has a highly experienced and knowledgeable management team who bring a wealth of relevant business and technical expertise to the company.
Dr. Duncan Henderson
Duncan has 20 years experience in the pharma industry, most recently in drug discovery with AstraZeneca, where he held Team and Project Leader positions working with small molecule, antibody and siRNA projects from target discovery stage through to lead identification and lead optimization. He also has extensive experience managing technology assessments and assessing in-license opportunities in a variety of disease and technology areas.
He is a biotechnology graduate of Leeds University and gained a PhD working with Streptomycetes at the John Innes Centre.
Kevin's career has been a lifetime in the medical devices industry where he has been CEO and Chairman of several quoted and private companies both in Europe and the USA. Between 1996 & 2003 he was one of the founder directors of Ferraris Group plc (FTSE: listed). He is an experienced entrepreneur, investor and executive and currently he is an investor and Chairman of Surface Transforms plc (AIM listed), Hallmarq Veterinary Imaging and Imorphics Ltd; a director of Acuity VCT plc and Octopus Titan VCT plc. Through a partnership, Salusinvest LP, he advises a number of EU & US listed med tech companies. He is a chemical engineer from Leeds University and has an MBA from Manchester Business School.
Dr. Curtis Dobson
NED & Founder
Curtis is a senior research fellow at the University of Manchester, focusing since the mid-1990s on the interactions of infectious agents with human proteins. His research has been funded by the BBSRC, the Wellcome Trust, Alzheimer's Research Trust and industry. Throughout his career Curtis has worked closely with industry, and in his University role he consults for the global medical device industry. Curtis founded Ai2 Ltd in 2005, to commercialize technology arising from an award-winning research project he had devised. He led the company's growth and development until late 2009, when he moved to his current technical role. Curtis is also IP Exploitation Coordinator for the University's Faculty of Life Sciences, one of the largest organisations of its type in Europe.
Johannah has 25 years financial and business advisory experience. She qualified as a Chartered Accountant in 1988, subsequently working for 14 years with KPMG in Germany and the UK in their international audit and business advisory departments. Since 2002 she has worked with a number of SMEs in a wide range of business sectors and particularly enjoys working with young and developing companies.
Dr. David Holbrook
Dr David Holbrook leads MTI's healthcare practice, joining the firm in 2003. David, a qualified physician, spent seven years in Global Business Development with Glaxo and Roche, subsequently heading Imperial College's spin-out operations, raising and managing the College's seed fund. At MTI, David has been responsible for the investment in, and subsequent sale of bone graft company ApaTech to Baxter International for over $300m. David also has an MA from Oxford University and an MBA from Harvard University.
Dr. Andrew Round
NED (SPARK Impact)
Andy is Investment Manager at SPARK Impact and member of the Investment Committee, his responsibilities include deal sourcing, making and closing investments and then managing portfolio companies to successful exits. Andy has invaluable experience of both sides of the funding process, having invested in and built up a portfolio of life sciences companies at IP-Group, as one of their Investment Managers and having raised £30-40 Million for a range of early stage companies and Ventures. Andy has a PhD in Biochemistry and his work became the foundation on which a North West Biotechnology company was founded, Micap which went on to be listed on AIM.
Dr. Philip Morgan
(Manager of Eurolens)
Philip is director of Eurolens Research at The University of Manchester where he is also a senior lecturer and program director for optometry. He manages clinical and laboratory research projects in conjunction with the contact lens industry, in addition to teaching at undergraduate and postgraduate level. Philip is vice-president of the International Society for Contact Lens Research and secretary of the International Association of Contact Lens Educators. He is an honorary item of the UK Association of Contact Lens Manufacturers, a Fellow of the American Academy of Optometry and the British Contact Lens Association, and an item of the UK College of Optometrists. He has authored over 160 papers, primarily relating to the clinical performance of contact lenses and the nature of the UK and international contact lens markets.